1. Galleria mellonella as an Antimicrobial Screening Model.
- Author
-
Barton TE, Duignan L, Kadioglu A, Fothergill JL, and Neill DR
- Subjects
- Animals, Drug Evaluation, Preclinical methods, Anti-Bacterial Agents pharmacology, Anti-Infective Agents pharmacology, Pseudomonas Infections microbiology, Pseudomonas Infections drug therapy, Moths microbiology, Moths drug effects, Larva drug effects, Larva microbiology, Pseudomonas aeruginosa drug effects, Disease Models, Animal
- Abstract
To combat the rising global issue of antibiotic resistance, the accelerated development of novel antibiotics is essential. Current preclinical antimicrobial development yields a significant number of leads that prove unsuitable either prior to or during clinical trials. To increase the efficiency of preclinical development, relevant, standardized, accessible, and cost-effective models must be developed. Galleria mellonella (greater wax moth) larvae are widely used as an infection model to assess microbial virulence, conduct drug toxicity testing, and serve as a preliminary means of evaluating the in vivo efficacy of novel antimicrobial compounds. These infection models have greater biological relevance than many in vitro screens of comparable throughput and decrease reliance on mammalian models when used as a pre-screen for antimicrobial testing. This protocol describes a standardized methodology for the optimization of G. mellonella infection models, which can be applied to bacterial species and antimicrobial therapeutics of choice. Using the WHO priority pathogen Pseudomonas aeruginosa as an exemplar, we outline steps that can be undertaken to develop a reproducible model of infection and therapeutic testing. This includes recommendations on experimental setup, sample preparation, and infection and treatment protocols. Integration of this model within preclinical antimicrobial development pipelines would decrease reliance on mammalian models, reduce the number of ineffective compounds reaching clinical trials, and ultimately increase the efficiency of preclinical antimicrobial development.
- Published
- 2024
- Full Text
- View/download PDF